Plasma gelsolin levels and outcomes after aneurysmal subarachnoid hemorrhage

Critical Care

Volumn 17, Issue 4, 2013, Pages

  Pan, Jian Wei ^a   He, Ling Na ^b   Xiao, Feng ^a   Shen, Jian ^a   Zhan, Ren Ya ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY OF TECHNOLOGY   (China)

Author keywords

Aneurysmal subarachnoid hemorrhage; Functional outcome; Gelsolin; Mortality

Indexed keywords

C REACTIVE PROTEIN; D DIMER; FIBRINOGEN; GELSOLIN; GLUCOSE; NIMODIPINE; VALPROIC ACID; BIOLOGICAL MARKER;

ADULT; ARTICLE; BRAIN ARTERY ANEURYSM; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; BRAIN VASOSPASM; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOGEN BLOOD LEVEL; FISHER SCORE; FOLLOW UP; FUNCTIONAL ASSESSMENT; GLASGOW OUTCOME SCALE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCORING SYSTEM; SEIZURE; SENSITIVITY AND SPECIFICITY; SUBARACHNOID HEMORRHAGE; VENTRICULOSTOMY CATHETER; WORLD FEDERATION OF NEUROLOGICAL SURGEONS SCORE; BLOOD; INTRACRANIAL ANEURYSM; MIDDLE AGED; SURVIVAL RATE; TREATMENT OUTCOME; TRENDS;

ADULT; BIOLOGICAL MARKERS; FEMALE; GELSOLIN; HUMANS; INTRACRANIAL ANEURYSM; MALE; MIDDLE AGED; SUBARACHNOID HEMORRHAGE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84880334975     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc12828     Document Type: Article

References (41)

1. Silacci P, Mazzolai L, Gauci C, Stergiopulos N, Yin HL, Hayoz D. Gelsolin superfamily proteins: key regulators of cellular functions. Cell Mol Life Sci 2004, 61:2614-2623. 10.1007/s00018-004-4225-6, 15526166.
2. Ito H, Kambe H, Kimura Y, Nakamura H, Hayashi E, Kishimoto T, Kishimoto S, Yamamoto H. Depression of plasma gelsolin level during acute liver injury. Gastroenterology 1992, 102:1686-1692.
3. Suhler E, Lin W, Yin HL, Lee WM. Decreased plasma gelsolin concentrations in acute liver failure, myocardial infarction, septic shock, and myonecrosis. Crit Care Med 1997, 25:594-598. 10.1097/00003246-199704000-00007, 9142022.
4. Huang S, Rhoads SL, DiNubile MJ. Temporal association between serum gelsolin levels and clinical events in a patient with severe falciparum malaria. Clin Infect Dis 1997, 24:951-954. 10.1093/clinids/24.5.951, 9142799.
5. Dahl B, Schiødt FV, Ott P, Gvozdenovic R, Yin HL, Lee WM. Plasma gelsolin is reduced in trauma patients. Shock 1999, 12:102-104. 10.1097/00024382-199908000-00002, 10446889.
6. Christofidou-Solomidou M, Scherpereel A, Solomides CC, Muzykantov VR, Machtay M, Albelda SM, DiNubile MJ. Changes in plasma gelsolin concentration during acute oxidant lung injury in mice. Lung 2002, 180:91-104. 10.1007/s004080000084, 12172902.
7. Rothenbach PA, Dahl B, Schwartz JJ, O'Keefe GE, Yamamoto M, Lee WM, Horton JW, Yin HL, Turnage RH. Recombinant plasma gelsolin infusion attenuates burn-induced pulmonary microvascular dysfunction. J Appl Physiol 2004, 96:25-31. 10.1063/1.1711178, 12730154.
8. Lee PS, Waxman AB, Cotich KL, Chung SW, Perrella MA, Stossel TP. Plasma gelsolin is a marker and therapeutic agent in animal sepsis. Crit Care Med 2007, 35:849-855. 10.1097/01.CCM.0000253815.26311.24, 17205019.
9. Mounzer KC, Moncure M, Smith YR, Dinubile MJ. Relationship of admission plasma gelsolin levels to clinical outcomes in patients after major trauma. Am J Respir Crit Care Med 1999, 160:1673-1681. 10.1164/ajrccm.160.5.9807137, 10556139.
10. Lee PS, Drager LR, Stossel TP, Moore FD, Rogers SO. Relationship of Plasma gelsolin levels to outcomes in critically ill surgical patients. Ann Surg 2006, 243:399-403. 10.1097/01.sla.0000201798.77133.55, 1448930, 16495706.
11. DiNubile MJ, Stossel TP, Ljunghusen OC, Ferrara JL, Antin JH. Prognostic implications of declining plasma gelsolin levels after allogeneic stem cell transplantation. Blood 2002, 100:4367-4371. 10.1182/blood-2002-06-1672, 12393536.
12. Xu JF, Liu WG, Dong XQ, Yang SB, Fan J. Change in plasma gelsolin level after traumatic brain injury. J Trauma Acute Care Surg 2012, 72:491-496.
13. Guo XC, Luo BY, Li XF, Yang DG, Zheng XN, Zhang K. Plasma gelsolin levels and 1-year mortality after first-ever ischemic stroke. J Crit Care 2011, 26:608-612. 10.1016/j.jcrc.2011.02.007, 21481565.
14. Zhao DQ, Wang K, Zhang HD, Li YJ. Significant reduction of plasma gelsolin levels in patients with intracerebral hemorrhage. Clin Chim Acta 2013, 415:202-206.
15. Chou SH, Lee PS, Konigsberg RG, Gallacci D, Chiou T, Arai K, Simmons S, Bauer D, Feske SK, Lo EH, Ning M. Plasma-type gelsolin is decreased in human blood and cerebrospinal fluid after subarachnoid hemorrhage. Stroke 2011, 42:3624-3627. 10.1161/STROKEAHA.111.631135, 3537515, 21940962.
16. Drake C. Report of World Federation of Neurological Surgeons Committee on a universal subarachnoid hemorrhage grading scale. J Neurosurg 1988, 68:985-986.
17. Fisher CM, Kistler JP, Davis JM. Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning. Neurosurgery 1980, 6:1-9. 10.1227/00006123-198001000-00001, 7354892.
18. Jennett B, Bond M. Assessment of outcome after severe brain damage. Lancet 1975, 1:480-484.
19. Schafer DA, Cooper JA. Control of actin assembly at filament ends. Annu Rev Cell Dev Biol 1995, 11:497-518. 10.1146/annurev.cb.11.110195.002433, 8689567.
20. Janmey PA, Stossel TP. Modulation of gelsolin function by phosphatidylinositol 4,5-bisphosphate. Nature 1987, 325:362-364. 10.1038/325362a0, 3027569.
21. Kwiatkowski DJ, Mehl R, Yin HL. Genomic organization and biosynthesis of secreted and cytoplasmic forms of gelsolin. J Cell Biol 1988, 106:375-384. 10.1083/jcb.106.2.375, 2114988, 2828382.
22. Kwiatkowski DJ, Janmey PA, Yin HL. Identification of critical functional and regulatory domains in gelsolin. J Cell Biol 1989, 108:1717-1726. 10.1083/jcb.108.5.1717, 2115573, 2541138.
23. Azuma T, Witke W, Stossel TP, Hartwig JH, Kwiatkowski DJ. Gelsolin is a downstream effector of rac for fibroblast motility. EMBO J 1998, 17:1362-1370. 10.1093/emboj/17.5.1362, 1170484, 9482733.
24. Witke W, Sharpe AH, Hartwig JH, Azuma T, Stossel TP, Kwiatkowski DJ. Hemostatic, inflammatory, and fibroblast responses are blunted in mice lacking gelsolin. Cell 1995, 81:41-51. 10.1016/0092-8674(95)90369-0, 7720072.
25. Lee WM, Galbraith RM. The extracellular actin-scavenger system and actin toxicity. N Engl J Med 1992, 326:1335-1341. 10.1056/NEJM199205143262006, 1314333.
26. Yin HL, Stossel TP. Control of cytoplasmic actin gel-sol transformation by gelsolin, a calcium-dependent regulatory protein. Nature 1979, 281:583-586. 10.1038/281583a0, 492320.
27. Kwiatkowski DJ, Stossel TP, Orkin SH, Mole JE, Colten HR, Yin HL. Plasma and cytoplasmic gelsolins are encoded by a single gene and contain a duplicated actin-binding domain. Nature 1986, 323:455-458. 10.1038/323455a0, 3020431.
28. Janmey PA, Lind SE. Capacity of human serum to depolymerize actin filaments. Blood 1987, 70:524-530.
29. Kwiatkowski DJ, Mehl R, Izumo S, Nadal-Ginard B, Yin HL. Muscle is the major source of plasma gelsolin. J Biol Chem 1988, 263:8239-8243.
30. Lind SE, Smith DB, Janmey PA, Stossel TP. Role of plasma gelsolin and the vitamin D-binding protein in clearing actin from the circulation. J Clin Invest 1986, 78:736-472. 10.1172/JCI112634, 423663, 3018044.
31. Haddad JG, Harper KD, Guoth M, Pietra GG, Sanger JW. Angiopathic consequences of saturating the plasma scavenger system for actin. Proc Natl Acad Sci USA 1990, 87:1381-1385. 10.1073/pnas.87.4.1381, 53479, 2154744.
32. Rosengart MR, Arbabi S, Bauer GJ, Garcia I, Jelacic S, Maier RV. The actin cytoskeleton: an essential component for enhanced TNFalpha production by adherent monocytes. Shock 2002, 17:109-113. 10.1097/00024382-200202000-00005, 11837785.
33. Bucki R, Georges PC, Espinassous Q, Funaki M, Pastore JJ, Chaby R, Janmey PA. Inactivation of endotoxin by human plasma gelsolin. Biochemistry 2005, 44:9590-9597. 10.1021/bi0503504, 16008344.
34. Goetzl EJ, Lee H, Azuma T, Stossel TP, Turck CW, Karliner JS. Gelsolin binding and cellular presentation of lysophosphatidic acid. J Biol Chem 2000, 275:14573-14578. 10.1074/jbc.275.19.14573, 10799543.
35. Osborn TM, Dahlgren C, Hartwig JH, Stossel TP. Modifications of cellular responses to lysophosphatidic acid and platelet-activating factor by plasma gelsolin. Am J Physiol Cell Physiol 2007, 292:C1323-1330.
36. Christofidou-Solomidou M, Scherpereel A, Solomides CC, Christie JD, Stossel TP, Goelz S, DiNubile MJ. Recombinant plasma gelsolin diminishes the acute inflammatory response to hyperoxia in mice. J Investig Med 2002, 50:54-60. 10.2310/6650.2002.33518, 11813829.
37. Tanaka J, Kira M, Sobue K. Gelsolin is localized in neuronal growth cones. Brain Res Dev Brain Res 1993, 76:268-271. 10.1016/0165-3806(93)90217-X, 8149595.
38. Furukawa K, Fu W, Li Y, Witke W, Kwiatkowski DJ, Mattson MP. The actin-severing protein gelsolin modulates calcium channel and NMDA receptor activities and vulnerability to excitotoxicity in hippocampal neurons. J Neurosci 1997, 17:8178-8186.
39. Endres M, Fink K, Zhu J, Stagliano NE, Bondada V, Geddes JW, Azuma T, Mattson MP, Kwiatkowski DJ, Moskowitz MA. Neuroprotective effects of gelsolin during murine stroke. J Clin Invest 1999, 103:347-351. 10.1172/JCI4953, 407902, 9927495.
40. Yildirim F, Gertz K, Kronenberg G, Harms C, Fink KB, Meisel A, Endres M. Inhibition of histone deacetylation protects wildtype but not gelsolin-deficient mice from ischemic brain injury. Exp Neurol 2008, 210:531-542. 10.1016/j.expneurol.2007.11.031, 18234195.
41. Güntert A, Campbell J, Saleem M, O'Brien DP, Thompson AJ, Byers HL, Ward MA, Lovestone S. Plasma gelsolin is decreased and correlates with rate of decline in Alzheimer's disease. J Alzheimers Dis 2010, 21:585-596.